Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | TDO2 | P48775 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | PKM | P14618 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | CASP6 | P55212 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192421 | 0.81 | ALDH1A1 (0.53) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL203781 | 0.81 | PDE10A (0.50) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL13914462 | 0.77 | MAPT (0.47) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1033969 | 0.77 | POLB (0.51) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4461933 | 0.75 | PDE10A (0.65) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8164006 | 0.75 | MAPT (1.00) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL18300579 | 0.75 | MAPT (1.00) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL30122552 | 0.75 | PDE10A (0.65) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL796948 | 0.75 | MAPT (0.43) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2749823 | 0.75 | MAPT (0.57) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436176-B2 | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-05-07 | — | — | US | claimed |
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | claimed |
| EP-1833827-B1 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | claimed |
| EP-1833827-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C¨Ý1,5¨NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074046-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | claimed |
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3350178-A1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | Pfizer Inc (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017046675-A1 | NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-6323200-B1 | THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. | 3M INNOVATIVE PROPERTIES COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | MAPT 246/4885KDM4E 1167/4885ALDH1A1 1603/4885 |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | MAPT 4076/4885KDM4E 3540/4885ALDH1A1 624/4885 |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | MAPT 4076/4885KDM4E 3540/4885ALDH1A1 624/4885 |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | DNMT1, NT5C, JMJD1C | MAPT 2712/4885KDM4E 119/4885ALDH1A1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.